Home/Filings/4/0000950170-25-023253
4//SEC Filing

Lee Tien-Li 4

Accession 0000950170-25-023253

CIK 0001774857other

Filed

Feb 18, 7:00 PM ET

Accepted

Feb 19, 4:35 PM ET

Size

9.0 KB

Accession

0000950170-25-023253

Insider Transaction Report

Form 4
Period: 2025-02-14
Lee Tien-Li
DirectorChief Executive Officer10% Owner
Transactions
  • Conversion

    Common Stock

    2025-02-14+41,3031,479,633 total
  • Purchase

    Common Stock

    2025-02-14$16.00/sh+16,542$264,6721,496,175 total
  • Conversion

    Series A Convertible Preferred Stock

    2025-02-14350,0020 total
    Common Stock (41,303 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    1,474,028
Footnotes (1)
  • [F1]The Series A Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series A Convertible Preferred Stock had no expiration date.

Documents

1 file

Issuer

Aardvark Therapeutics, Inc.

CIK 0001774857

Entity typeother

Related Parties

1
  • filerCIK 0001940120

Filing Metadata

Form type
4
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 4:35 PM ET
Size
9.0 KB